dronabinol (BX-1) / Bionorica - LARVOL DELTA

Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol (clinicaltrials.gov) - P2 | N=170 | Completed | Sponsor: Charite University, Berlin, Germany | Active, not recruiting ➔ Completed | Trial completion date: Jun 2025 ➔ Jan 2025

Trial completion • Trial completion date • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

DIsCOvER: Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer (clinicaltrials.gov) - P3 | N=109 | Completed | Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie | Active, not recruiting ➔ Completed

Trial completion • Chemotherapy-Induced Nausea and Vomiting • Hepatology • Oncology • Solid Tumor

Treating Nightmares in Posttraumatic Stress Disorder with Dronabinol (clinicaltrials.gov) - P2 | N=176 | Active, not recruiting | Sponsor: Charite University, Berlin, Germany | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

DIsCOvER: Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer (clinicaltrials.gov) - P3 | N=109 | Active, not recruiting | Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie | Recruiting ➔ Active, not recruiting

Enrollment closed • Metastases • Chemotherapy-Induced Nausea and Vomiting • Gastrointestinal Cancer • Hepatology • Oncology • Solid Tumor

Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol (clinicaltrials.gov) - P2 | N=176 | Recruiting | Sponsor: Charite University, Berlin, Germany | Trial completion date: Jul 2023 ➔ May 2025 | Trial primary completion date: May 2023 ➔ Jan 2025

Trial completion date • Trial primary completion date • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer (clinicaltrials.gov) - P3 | N=104 | Recruiting | Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie | Trial completion date: Mar 2024 ➔ Sep 2024 | Trial primary completion date: Mar 2024 ➔ Sep 2024

Trial completion date • Trial primary completion date • Chemotherapy-Induced Nausea and Vomiting • Gastrointestinal Cancer • Hepatology • Oncology • Solid Tumor

Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer (clinicaltrials.gov) - P3 | N=104 | Recruiting | Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie | Trial completion date: Sep 2023 ➔ Mar 2024 | Trial primary completion date: Sep 2022 ➔ Mar 2024

Metastases • Trial completion date • Trial primary completion date • Chemotherapy-Induced Nausea and Vomiting • Gastrointestinal Cancer • Hepatology • Oncology • Solid Tumor • CRP

Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol (clinicaltrials.gov) - P2 | N=176 | Recruiting | Sponsor: Charite University, Berlin, Germany | Trial completion date: May 2022 ➔ Jul 2023 | Trial primary completion date: May 2022 ➔ May 2023

Trial completion date • Trial primary completion date • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer (clinicaltrials.gov) - P3; N=104; Recruiting; Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie; Trial completion date: Jun 2022 ➔ Sep 2023; Trial primary completion date: Jun 2022 ➔ Sep 2022

Clinical • Trial completion date • Trial primary completion date • Chemotherapy-Induced Nausea and Vomiting • Gastrointestinal Cancer • Hepatology • Oncology • Solid Tumor • CRP

BX-1 in Spasticity Due to Multiple Sclerosis (clinicaltrials.gov) - P3; N=397; Completed; Sponsor: Bionorica SE; Recruiting ➔ Completed

Clinical • Trial completion • CNS Disorders • Movement Disorders • Multiple Sclerosis

Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol (clinicaltrials.gov) - P2; N=176; Recruiting; Sponsor: Charite University, Berlin, Germany; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

BX-1 in Spasticity Due to Multiple Sclerosis (clinicaltrials.gov) - P3; N=384; Recruiting; Sponsor: Bionorica SE; Trial completion date: Jul 2020 ➔ Feb 2021; Trial primary completion date: Jul 2020 ➔ Feb 2021

Clinical • Trial completion date • Trial primary completion date • CNS Disorders • Multiple Sclerosis

Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol (clinicaltrials.gov) - P2; N=176; Not yet recruiting; Sponsor: Charite University, Berlin, Germany

Clinical • New P2 trial • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer (clinicaltrials.gov) - P3; N=140; Recruiting; Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open